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Summary 
Structural similarities between host self-antigens and infectious organisms may be involved in 
the expression ofautoimmune reactivity and development of autoimmune disease.  The unique 
eye pathology  associated with  Onchocerca volvulus  infection,  particularly  the  development of 
posterior segment lesions, may be promoted by such autoreactive responses. Ov39 is a parasite- 
derived  antigen  that  has  been  shown  previously  to  be  antigenically  cross-reactive  with  a 
44,000-Mr host ocular component. A clone, designated hr44, was isolated from a cDNA library 
of human  retina by immunoscreen using serum to  Ov39.  A  monoclonal antibody raised to 
Ov39 also reacted with hr44 and gave evidence for a shared conformational epitope. The pri- 
mary structure analysis showed that identities between the antigens are limited and confined to 
small  peptides.  The  cross-reactivity between  the  antigens  appears  to  involve  T  cells,  since 
Ov39-specific T  cells can be stimulated by hr44, a neural-specific antigen. Based on secondary 
structure prediction, hr44 has the typical features of a membrane-associated type I antigen with 
an amino-terminal extracellular domain, mAbs and antisera localized the antigen in the optic 
nerve, neural retina,  retinal pigment epithelium, as well as the epithelial layers of ciliary body 
and iris. 
O 
nchocerciasis  (river  blindness)  is  a  chronic  parasitic 
disease caused by the filarial  nematode Onchocerca vol- 
vulus.  The clinical manifestations have been well described 
(1-3),  and  sclerosing keratitis,  iridocyclitis,  optic  neuritis, 
and chorioretinitis account for significant visual morbidity 
(4).  Anterior  segment disease  has been  directly associated 
with intensity of infection as measured by microfilarial load 
(5-7).  The  inflammatory responses  directed  against dying 
microfilariae are considered the main cause of these patho- 
logical changes  (8,  9).  However, much of the blindness is 
caused by disease of the posterior segment, namely, inflam- 
mation of the choroid, retina, and optic nerve, as well as at- 
rophy  of these  tissues  (3,  10,  11).  The  pathogenesis  is 
poorly  understood  and  an  association  with  microfilarial 
burden is equivocal (5-7, 12). Involvement ofantoimmune 
reactivity in  the  development  of ocular  onchocerciasis  is 
one of several mechanisms that have been suggested (13). 
Evidence in  support  of a  role for autoimmune  mecha- 
nisms in the pathogenesis of chorioretinopathy comes from 
several observations. A longitudinal study of patients showed 
progression of chorioretinal  lesions,  predominantly  at the 
level of the retinal pigment epithelium,  despite the reduc- 
tion  of microfilarial  burden  by  chemotherapy  (11).  We 
have previously described Ab cross-reactivity between the 
recombinant antigen  Ov39  of O.  volvulus  and  a  44,000-M  r 
component of bovine and human retinal pigment epithelial 
cells  (14)  that was subsequently shown to be neurospecific 
and present in those tissues  affected by ocular onchocercia- 
sis (15).  Here, we report cross-reactivity between the para- 
site  and  host  ocular  antigen  (designated  hr44)  on the  Ab 
and  T  cell level,  describe  its  molecular organization,  and 
discuss  it as a target molecule for antiparasite-directed im- 
mune responses. 
Materials and Methods 
Cloning Experiments,  Screening Methods,  and DNA  Sequencing. 
Clone hr44  was isolated from a kgtl 1 expression library of hu- 
man retinal tissue (Clontech Laboratories,  Inc., Palo Alto,  CA). 
To identify  the  antigen-expressing  bacteriophage  clone,  the li- 
brary was screened as described before using rabbit serum raised 
to the recombinant parasite antigen  Ov39 expressed in pEX34b 
(14).  For this  purpose,  the  serum was  extensively  preabsorbed 
against whole  bacterial  extracts  of Escherichia coli PM1090  and 
pure  ~-galactosidase  (14). Recombinant-phage DNA was pre- 
pared as  previously  described  (14). The  cDNA insert  was ob- 
tained  by EcoRI digest and purified using the QIAEX Gel Ex- 
traction system (Qiagen, Hilden, Germany). The sequence  of both 
cDNA strands,  cloned into  pBluescript  II SK  +  (Stratagene,  La 
Jolla, USA), was determined using the Taq DNA Polymerase Se- 
quencing  System (United States Biochemical  Corp., Cleveland, 
OH). The primers used were both specific for pSK  § and internal 
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was performed using the programs of R.  Staden and of the Ge- 
netics Computer Group [GCG]  (Madison, WI), which included 
programs for the  secondary structure analysis  of amino acid se- 
quences based on various methods (16-18). The FASTA program 
by Pearson and Lipman  (19)  was  used for nucleotide sequence 
comparisons with entries in EMBL and NEWEMBL. Protein se- 
quences were compared with entries in the SwissProt library. 
The cDNA of hr44 and Ov39 were both cloned into the ex- 
pression  vector  pTrcHisB  (Invitrogen,  San  Diego,  CA).  The 
cDNA  encoding  Ov39  was  derived  from  the  construct  in 
pEX34b (14) by EcoRI digest and purification with the QIAEX 
gel extraction system. Two truncated versions of hr44 were also 
constructed for expression in pTrcHisB. One truncated molecule, 
designated hr44-Sal, was  expressed after restriction digest of the 
plasmid with  Sall  (single restriction site  at position  820  of the 
cDNA) and HindllI (single restriction site in the vector down- 
stream of the cDNA insert) to remove 362 nucleotides from the 
3' end of the cDNA. The plasmid was religated after fill in reaction 
with Klenow fragment (20).  For the expression of a second trun- 
cated molecule, designated hr44-3, a PCR product was generated 
from  part  of the  cDNA  using the  primers  5'GGATCGTTA- 
GGATTGTT and 5'ACGACGATGACGATAA, complementary 
to position 641-657 of the coding strand of the cDNA insert and 
complementary to  pTrcHisB position 493-508  upstream to  the 
multiple cloning region,  respectively.  The  PCR  fragment was 
cloned into pCR.TMII (lnvitrogen) and subsequently isolated from 
the plasmid after digest with XhoI (restriction site in the multiple 
cloning region  of pTrcHisB)  and  HindlII  (restriction  site  in 
pCRTMII). This allowed the directional reinsertion of this frag- 
ment into  XhoI-  and HindIIl-digested pTrcHisB  for  in-frame 
expression.  An irrelevant antigen derived from  O.  volvulus and 
designated Ov3.11  (Braun,  G.,  unpublished data)  was  also  ex- 
pressed in pTrcHisB and used for control experiments. 
Production and Purification of Recombinant Antigens.  All  recom- 
binant antigens used in this study were expressed from pTrcHisB 
in E. coli NM522 upon induction with 0.75 mM isopropy113-D- 
thiogalatoside at a density of 2-3 ￿  108 cells ￿9 ml  -I. After 4 h, the 
cells were harvested from the LB culture medium (20) and lysed 
using a French press.  The antigens were purified from the cytoso- 
lic fraction by column metal chelate chromatography using Pro- 
Bond resin (Invitrogen), as recommended by the supplier. A sec- 
ond  purification  step  was  conducted  by  gel  filtration  using 
Sephacryl S-200 (Pharmacia, Uppsala, Sweden) and PBS for elu- 
tion. The purified antigens were used for immunizations to pro- 
duce  B  cell hybridomas and reactive  T  cells  and were  used in 
ELISA and T  cell response assays. 
Antisera, SDS-PAGE, and Western Blot Analysis.  Production of 
rabbit sera to  native 44,000-M  r antigens of bovine optic  nerve 
and  to  Ov39,  expressed  as  fusion  protein  from  pEX34b  and 
pGEXI,  was  described  elsewhere  (14,  15).  Hr44,  immobilized 
onto  EMphaze  biosupport  material  (Pierce,  Amsterdam,  The 
Netherlands), was used to affinity purify specific Abs from serum 
to native ocular antigens. The Abs were eluted with 0.1 M  gly- 
cine-HCl,  pH  2.8,  and  neutralized  with  Tris-HC1,  pH  8.8. 
Eluted Abs were made up to the original volume of serum. SDS- 
PAGE  and Western blot analyses were  performed  as  described 
previously (14). 
B Cell Hybridomas, ELISA Assays, and Synthetic Peptides. mAbs 
were produced against Ov39 and hr44, both expressed in pTrcHisB. 
6-wk-old BALB/c mice received two injections of the respective 
antigen. The first injection of 10 ~g antigen in FCA was adminis- 
tered intraperitoneally. The second immunization with 20 Ixg of 
the antigen resuspended in PBS followed 3 wk later by the same 
route.  The spleen was removed 4  d  after the second immuniza- 
tion.  B  cell  hybridomas  were  produced  using  the  P3  X63 
Ag8.653 cell line (21) as a fusion partner for the sensitized spleen 
cells following the protocol by Galfre and Milstein (22).  Cell cul- 
ture  supematants  were  tested  by  ELISA  for  reactivity  against 
Ov39, hr44, the control antigen Ov3.11, and the synthetic pep- 
tide  MGGSHHHHHHGMASMTGGQQMGRDLYDDDD- 
KDPSSRSAAGTIW,  which  represents  the  carrier  peptide  of 
pTrcHisB. This peptide was HPLC purified and supplied by Dr. 
L.  Packman  (Department of Biochemistry,  University of Cam- 
bridge). For ELISA, the peptide was resuspended in PBS (0.1 ~g " 
ml+l), and Ov39 and Ov3.11  were resuspended in 0.05 M  car- 
bonate buffer at a concentration of 1 btg ￿9 m1-1 and 0.5 txg ￿9 ml  -~, 
respectively. ELISA plates were coated overnight, hr44 was resus- 
pended in distilled water at a concentration of 5 p~g ￿9 mli  and 
dried onto the plate by evaporation. Ab binding was detected by 
using peroxidase-labeled  goat  anti-mouse y  chain-specific  Ab 
(Sigma, Dorset, UK) and ABTS (2,2'-azino-bis (3-ethylbenzthia- 
zoline 6-sulfonic acid) diammonium; Sigma). The mAbs to Ov39 
are  39/24C5  and 39/21A1.  mAb  44/72C2  was  obtained after 
immunization with hr44. All cell lines were cloned at least three 
times by the  limiting dilution method.  The  mAbs used  in the 
study were of the IgG1 subclass,  as determined by the red cell ag- 
glutination assay (Serotec, Oxford, UK), and they were obtained 
from  serum-free tissue culture supernatants that  had been  con- 
centrated 50￿  by ammonium sulfate precipitation. 
Based on the primary structure of Ov39 (14),  a set of 36 pep- 
tides  was  purchased  from  Cambridge  Research  Biochemicals 
(Cambridge,  UK).  Each  of these  peptides was  immobilized on 
"pins" and consisted of 10 amino acids overlapping by 7 residues. 
These  peptides  were  used  in an ELISA-type assay,  where  sera 
raised against Ov39 expressed from pEX3b, pGEXI, and the car- 
rier expressed from pEX34b (14) were used in a 1:5,000 dilution. 
Serum raised to the electroeluted ocular antigens was used in 1 : 100 
dilution. The bleeds taken from the rabbits before immunization 
were also tested. The assays were carried out in accordance with 
the supplier's instructions. 
T Cell Response Assays.  Lewis  rats  (Harlan,  Bicester,  UK) 
were immunized once by plantar injection with 50 p,g of antigen 
in 100 txg FCA supplemented with 5 mg￿9 m1-1 ofmycobacteria 
H37Ra,  whole organism (Difco Laboratories, Detroit, MI). The 
antigens used were Ov39, hr44, and Ov3.11 as control. 10 d after 
immunization, the cells of the inguinal lymph nodes were isolated 
and cultured to establish antigen-specific T  cell lines following a 
protocol by Ben-Nun et al.  (23).  The cells were restimulated at 
intervals of 10-14 d  using irradiated (6,125 rads)  rat thymus-de- 
rived APCs. Specific T  cell lines for Ov39 and hr44 were stimu- 
lated five times and the specific T  cell line for Ov3.11 four times 
with the respective homologous recombinant antigen at a  con- 
centration of 2.5 p.g  ￿9  1TI1-1  before stimulation experiments were 
carried out with heterologous antigens at various concentrations. 
Stimulation was measured after incorporation of [3H]thymidine, 
25  Ci  ￿9 mmo1-1  (Amersham  International,  Amersham,  UK), 
which was added at 2  ￿  10 -4 ~Ci per well for 18-20 h. 
Immunocytochemistry.  Rat  eyes were  fixed in 4%  glutaralde- 
hyde in PBS. The sections were mounted on slides  coated with 
APES  (3-aminopropyltriethoxy-silane) (Sigma)  (24).  The  tissue 
sections  were  treated  with  'STUF'  (Serotec  Unmasking Fluid) 
following the supplier's recommendations. Indirect immunoper- 
oxidase staining was performed as described elsewhere (15) using 
rabbit  serum  (dilution range  1 : 20-1 : 160)  and  mAbs  (dilution 
range 1:5-1:160 of the 50￿  concentrate). Species-specific biotin- 
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used for detection of Ab binding. 
Controls for specificity  of immunostaining with rabbit  antise- 
rum were (a) omission of the primary Ab; (b) use of serum taken 
before immunization; and (c) use of an irrelevant  antiserum raised 
following the same immunization protocol using FCA. The con- 
trols  for specificity  of immunostaining with  the mAbs were  (a) 
omission of the primary Ab; and  (b) use  of irrelevant  mAb 39/ 
21A1. 
Results 
hr44,  a  cDNA  Clone  Derived from  Human  Retinal  Tissue. 
To characterize the ocular antigen and the molecular basis 
of the immunological cross-reactivity, 5  ￿  105 phages of a 
cDNA  library  prepared  from  human  retinal  tissue  were 
screened using rabbit serum raised against Ov39 expressed 
in pEX34b.  Of the five clones obtained,  one expressed an 
N155,000-Mr antigen with [3-galactosidase, which was de- 
tected by Western  blot  (data  not shown).  This  clone was 
designated  hr44.  The  cDNA  insert  consists  of 1,183  bp 
containing  one  open  reading  frame  encoding  338  amino 
acid residues  with  a  calculated molecular mass of 37281.3 
D  (Fig.  1).  The 3'  untranslated  region downstream of the 
TAG stop codon at position  1016 consists of 167 bp. This 
region is highly AT rich,  and it has several stop codons in 
all three reading frames. It does not contain a poly (A) + tail 
nor a  polyadenylation sequence,  presuming the  3'  EcoRI 
site is a gene-specific sequence rather than a restriction site 
introduced  by  added  linker  sequences  in  the  process  of 
cDNA cloning. 
Serum to the  native  44,000-M~ antigen was used to es- 
tablish the identity of the clone hr44.  As demonstrated by 
Western  blot,  this  serum,  like  the  serum  to  Ov39,  reacts 
with a 44,000-M  r component of optic nerve (Fig. 2). It also 
recognizes the  recombinant  antigen  hr44,  which  was  ex- 
pressed  in  an  inducible  fashion  from  pTrcHisB  (Fig.  3). 
This  reactivity  is  not based  on  recognition  of the  carrier 
peptide,  since  the  serum  does  not  react  with  the  control 
antigen  Ov3.11  (data  not shown).  Hr44-specific,  affinity- 
purified Abs of this serum were used in Western blot and 
shown to react with a 44,000-Mr antigen of bovine retina 
(Fig. 4). This provides unequivocal evidence for clone hr44 
to represent  the  native  ocular antigen  originally identified 
by serum to the parasite antigen Ov39. 
mAbs to hr44 and 0v39.  Additional  evidence  in  sup- 
port of the identity ofhr44 is provided by data obtained us- 
ing mAbs.  Ab  39/24C5,  one  out  of five mAbs to  Ov39, 
was demonstrated to cross-react with hr44 by Western blot 
(Fig. 5). The cross-reactivity of 39/24C5 was not based on 
recognition of the carrier peptide,  since ELISA results have 
shown that this  mAb does not react with  the  control nor 
with  the  synthetic  carrier peptide  (Fig.  6).  Binding of the 
antigens to ELISA plates was monitored using an mAb 39/ 
21A1, which is specific for the carrier peptide of pTrcHisB 
(Fig.  6, inset). None of the  11  other mAbs to recombinant 
hr44  that have been  characterized  so far recognize Ov39. 
mAb  44/72C2  recognizes  hr44,  hr44-Sal,  and  hr44-3  by 
Western blot and ELISA (data not shown). 
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gaat  t  c  c  ggAAGAC  ACTTGAAACTGATAC  AGTTACAGGTAAGTCTGGTGAGAAG  ATTGAC  60 
(E) (F) (R)  K  T  L  E  T  D  T  V  T  G  K  S  G  E  K  I  D  20 
TACTCTACAACACCTCGAATTGATGAA%~C~  GTG  ACAAC~TTATCGCTTAGTTGAAGAT  120 
Y  S  T  T  P  R  I  D  E  W  R  D  K  G  Y  R  L  V  E  D  40 
GGTTTCGCTGAAGC  AGGC  AC  AC  CGGTTTATGATGATAATGATGATGTCGAAC  AAATCTTT  180 
G  F  A  E  A  G  T  P  V  Y  D  D  N  D  D  V  E  Q  I  F  60 
ATCGTTAAATTGGATC  ATGATACTGC  AC  C  AGTTC~CAAATGATC  CAC  ATGAAC  C  AGAA  240 
I  V  K  L  D  H  D  T  A  P  V  G  P  N  D  P  H  E  P  E  80 
AC  AC  CAATC  AATC  C  AAACGATCC  AAATGGAC  C  A.kAGTGGC  CAGC  TAAGGATAGC  TACAC  A  300 
T  P  I  N  P  N  D  P  N  G  P  K  W  P  A  K  D  S  Y  T  100 
AAAC  AATATACGTC  AACGGTTCATTTTGTAGATGAAAAC  GGTAATAAAC  TAC  AC  GATTAT  360 
K  Q  Y  T  S  T  V  H  F  V  D  E  N  G  N  K  L  H  D  Y  120 
AACG  TTC  AAAC  ATC  AAATTGGACAC  GAAC  ATTGATTGTC  GATAAGGCTACTC~TGAAATC  420 
N  V  Q  T  S  N  W  T  R  T  L  I  V  D  K  A  T  G  E  I  140 
TTGAATCCAGATGAAGCATGGCATTCTGATATTG  ATAAGTATTC  TGATG  TCAAAGTTGAT  480 
L  N  P  D  E  A  W  H  S  D  I  D  K  Y  S  D  V  K  V  D  160 
CCTATTA~TACTATACTGAC  CGCAATAG'/~TACC  AGGTGAAGTAGCAC  AACAACAA  540 
P  I  K  G  Y  Y  T  D  R  N  S  V  P  G  E  V  A  Q  Q  Q  180 
GATATTGTGAATAC  GGTTGTTTATAAGCA~TTGGTAAG ATTGTACCGGTT~ATCC  ATC  A  600 
D  I  V  N  T  V  V  Y  K  Q  I  G  K  I  V  P  V  D  P  S  200 
~  C  C  AAT'I~  C  AGA'I~C AC  C.~CACCAC.~I~TACAG/~AC~2C T.~.CGATCC~C T  660 
G  N  P  I  P  D  A  P  T  P  Q  Y  R  N  N  P  N  D  P~T  220 
'2 
AAGG  TTATC  GTAACGAATAeGC  CAGAAATTC  C  AGGTATGACACCAGAAGTACCAAGTGTT  720 
K  V  I  V  T  N  T  P  E  .I.P  G  M  T  P  E  .V.P  S  v  240 
AC  AC  C  AGAAAATC  C  AGGTGAAGATACAC  C  AATTGTTTAC  AACAAGGTTGAAACAC  CAAC  A  780 
T  P  E  N  P  G  E  D  T  P  I  V  Y  N  K  V  E  T  P  T  260 
CCAAAGACAGTAGATGTGACAC  C  AGAAACGCCGAAAACAGTCGACGTTACGTCAGAAAC  A  840 
P  K  T  V  D  V  T  P  E  T  P  K  T  V  D AV  T  S  E  T  280 
T 1 
C  CAAAGGCAAC  ACC  AGTTAAAACTGCGC  C  TCAAGTTGAAAAAGTTAAGGCGCC  AGAATTA  900 
P  K  A  T  P  V  K  T  A  P  Q  V  E  K  V  K  A  P  E  L  300 
CCAC  AAACTGGTGAAAAGC  AAAAT  AAGGC  GTTAAC  TGC  C  GTCGGTGC  ATCTATTATGAC  T  960 
P  Q  T  G  E  K  Q  N  K  A  L  T  A  V  G  A  S  I  M  T  320 
GGTC  TATTAGGAATCCTTGC  CT'FfGCTAAGAAAAAGAAGGATGACAAAGAAATCTAGTC  A  1020 
G  L  L  G  I  L  A  F  A  K  K  K  K  D  D  K  E  I  "  338 
TTTGGTTTAAGAAAGAAGAGTCGAAAGAC  TCTT~TFFIq%TTGGTGTGCGTGATAATAGGT 1080 
TAATTATTTTTTGGTAATATCTCATGAAAAACTATGCATAATTTTAGGTGCAAATTAC,  C  C  1140 
AACGATATATCAATA'I-~T~"~'ATATAATAGTTGC  C  CGGAATTC  1183 
Figure  1.  cDNA sequence and  deduced protein sequence of hr44. 
The single-letter amino acid code is given below the first nucleotide of 
each codon. The amino-terminal three residues are encoded by the linker 
sequence. Repetitive amino acid sequences are underlined. Arrows 1 and 
2 indicate the 3' end of the truncated molecules hr44-S.al and hr44-3, re- 
spectively, These sequence data are available from EMBL under accession 
number X91103. Composition: A, 16; G, 19; L, 11; Q, 11; v, 33; D, 32; 
H, 5; M, 2; R, 7; W, 4; E, 24; I, 19; N, 20; S, 12; Y, 12; F, 5; K, 30; P, 
38; T, 38. Total: 339. 
The Primary Structure of hr44.  The  primary  structure  of 
hr44 was deduced from the nucleotide sequence and is pre- 
sented  in  Fig.  1.  Proline  and  threonine,  each  comprising 
11.2% of the total amino acid content, are the most abun- 
dant. Unlike threonine, the proline residues are not equally 
distributed  throughout  the  molecule.  A  cluster  of proline 
residues is found between positions 70 and 94.55% of the 
proline residues, however, are positioned between residues 
203 and 298. A  number of repetitive sequences are located 
in this area. The fragment of the protein up to position 310 
is  predominantly  hydrophilic.  This  is  consistent  with  the 
finding that the purified recombinant antigen is soluble in 
aqueous solution. The amino acid sequence between posi- 
tions 310 and 329, however, has an exclusively apolar char- Figure  2.  Recognition  of  the 
44,000-M  r antigen in a total extract 
of bovine optic nerve. Proteins were 
electrophoreticaUy  separated  on  a 
10% acrylamide/SDS gel  under re- 
ducing  conditions,  and  the  antigen 
was detected by Western blot using 
rabbit sera. (Lane  1) serum taken be- 
fore  immunization  with  Ov39. 
(Lane  2)  Serum  raised  against  re- 
combinant  Ov39  expressed  from 
pEX34b.  (Lane  3) Serum taken be- 
fore immunization with ocular anti- 
gens.  (Lane  4)  Serum raised  against 
the  44,000-Mr  antigen  of  optic 
nerve. 
acter with typical features of a  transmembrane domain,  not 
interrupted by nonpermissive residues such as K,  H,  R,  D, 
E,  N,  or Q.  This sequence is predicted to form the helical 
structure  of  a  single  transmembrane-spanning  region.  A 
cluster of consecutive basic residues,  KKKKDDK,  is found 
Figure  4.  Recognition of the 44,000-Mr  native ocular antigen by af- 
finity-purified Abs. The antigens  of an extract of bovine retina (A) and a 
lysate of E. coli NM522 induced to express hr44 from pTrcHisB (/3) were 
electrophoreticaLly  separated  on a  10% acrylamide/SDS gel,  and the re- 
combinant and native antigens were detected by Western blot. (A, lane 1) 
Serum taken before immunization with the ocular antigens, dilution 1 : 800, 
(A, lane 2) serum taken after  immunization with the native 44,000-M~ 
optic nerve antigen, dilution 1 : 800. (A, lane 3) Abs that were attinity-pu- 
rifled from serum to native ocular antigen using the recombinant antigen 
hr44, dilution 1 : 50.  (B, lane  1)  Serum taken before immunization with 
the native 44,000-M  r ocular antigen, dilution I : 800. (B, lane 2) rabbit se- 
rum to the native 44,000-M  r ocular antigen, dilution 1 : 800.  (B, lanes 3 
and 4) serum to the native antigen depleted of Abs specific for recombi- 
nant hr44, dilutions 1 : 800 and 1 : 200, respectively.  (B, lanes 5 and 6) af- 
finity-purified Abs specific for hr44,  dilutions 1 : 200 and  1 : 50,  respec- 
tively. These Abs were used in A, lane 3. 
Figure 3.  Induced expression of the hr44 from pTrcHisB in E.  coli 
NM522. Proteins of an uninduced (right) and an induced (left) bacterial ly- 
sate were electrophoretically  separated on a 10% acrylarmde/SDS  gel un- 
der reducing condition, and the antigen was detected by Western blot us- 
ing rabbit sera. (Lane  1)  Serum taken before immunization with Ov39. 
(Lane  2)  Serum  taken after  immunization with  Ov39  expressed  from 
pEX34b.  (Lane  3)  Serum taken before immunization with ocular anti- 
gens.  (Lane  4)  serum taken after immunization with  serum raised  the 
44,000 Mr antigen of the optic nerve. 
at the very carboxy  terminus at position 330. This is consis- 
tent with the requirement of positively charged residues in the 
cytoplasmatic segments oftransmembrane  proteins (25,  26). 
The  sequence  from  residue  300-329  has also  some  ho- 
mology  with  the  proposed  sites  of cleavage  and  glycosyl- 
phosphatidylinositol attachment sequences found in glycosyl- 
phosphatidylinositol  (GPI)l-anchored proteins of eucaryotes. 
At position 300-305,  the sequence  contains a  hexapeptide, 
LPQTGE,  identical  to  the  consensus  sequence  that  has 
been described as  the membrane  anchor region  for surface 
proteins,  particularly  of Gram-positive  bacteria  (27).  This 
sequence of hr44 has homology  with GPI-anchored  mole- 
cules associated with cell adhesion, including the neural cell 
adhesion  molecule  N-CAM;  the  lymphocyte  function-as- 
sociated protein LFA-3, and the Dictyostelium discoicleum con- 
tact site A  molecule  CsA,  compiled  by  Ferguson  and Will- 
iams  (28).  The  sequence  downstream  of the  hexapeptide 
has  homology  with  GPI-anchored  cell  surface  molecules 
1Abbreviation used in this paper: GPI, glycosyl-phosphatidyhnositol. 
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Figure 5.  Recognition of Ov39 and hr44 by the cross-reactive mAb 
39/24C5. Bacteria extracts were electrophoretically  separated on a 10% 
polyacrylamide/SDS  gel, and the antigens  were detected by Western blot. 
(A) Serum to Ov39. (B) Serum to native 44,000-Mr optic nerve  antigen. 
(C) mAb 39/24C5. (Lanes 1 in A and B) Lysate of uninduced E.  coil 
(Lanes 2 in A and B)  Lysate of E.  cell induced to  express hr44 from 
pTrcHisB. (Lane 3)  Lysate of E.  coli induced to  express Ov39 from 
pTrcHisB. (Lane 1 in C) Lysate orE. coli induced to express hr44. (Lane 2 
in C) lysate ofE. coli induced to express Ov39. 
such as the acetylcholinesterase of Drosophila,  liver alkaline 
phosphatase, and gp190 of Plamodiumfalciparum.  The hr44 
clone does not contain the amino terminus of the antigen, 
and a signal sequence could not be predicted. 
Primary  Structure  Comparisons.  Comparative  analysis  of 
the primary structures of hr44 and Ov39 showed that the 
two  antigens are not homolognes, and the local identities 
found between these  antigens are  not  extensive  (Fig.  7). 
With reference to the respective amino acid residues, these 
are located at positions 129-140  (hr44)  and 88-99  (Ov39) 
with 41.7% identity in the  11-amino acid overlap  (Fig.  7 
A);  at positions  133-145  (hr44)  and 99-111  (Ov39)  with 
30.8% identity in the  12-amino acid overlap (Fig. 7  B);  at 
positions  143-147  (hr44)  and  55-59  (Ov39)  with  60.0% 
identity in the 5-amino acid overlap (Fig. 7  C); and at posi- 
tions 248-255  (hr44)  and 18-25  (Ov39) with 62.5% iden- 
tity in the  8-amino acid overlap (Fig. 7  D).  This localizes 
identities in three areas of Ov39. In hr44, the identities are 
confined to  two  areas  comprising residues  129-147  and 
248-255. 
Both  hr44  and  Ov39  were  compared  with  entries  of 
DNA and protein data bases.  Neither hr44 nor Ov39 is ho- 
mologous to any of the registered protein sequences to an 
extent that might give any information as to the potential 
functions of these antigens. For Ov39, however, sequence 
identity was found with bovine and human visual rhodop- 
sin over a stretch of eight residues. The octapeptide CAV- 
Figure 6.  ELISA demonstrating the  cross-reactivity between Ov39 
and hr44 using  the mAb 39/24C5. ELISA plates were coated with opti- 
mum dilutions of the following  antigens, Ov39, hr44, hr44-Sal, Ov3.11, 
and the  synthetic peptide representing the  carrier of pTrcHisB. Plates 
were probed with doubling dilutions of 39/24C5 and 39/21A1 (inset), 
which are specific for the carrier  peptide. The reactivity  of 39/24C5 with 
each antigen was detemlined at a time point when the control Ab 39/ 
21A1 gave an OD  of ~1.8.  ~,  Ov39; +,  hr44;  A  , 
hr44-Sal;  r  , Ov3.11;  []  , carrier. 
PPFVG residue 10-17 of Ov39 is 75% identical to human 
rhodopsin residue 167-174 comprising CAAPPFAG. 
LinearEpitopesofOv39.  Immunological  cross-reactiv- 
ity between Ov39 and hr44 may either be based on linear 
sequences and/or on recognition of discontinuously posi- 
tioned residues. Whether or not linear sequences of Ov39 
are recognized by sera was tested by ELISA using a set of 
36 peptides (Fig. 8). Rabbit sera to two constructs of Ov39 
were used in these experiments. Both sera recognize pep- 
tides 4, 5,  17, and 18.  In addition, sera to Ov39 expressed 
from pGEXI also recognizes peptides 6, 7, and 16  (Fig. 8, 
B and C). Serum raised against the electroeluted 44,000-Mr 
optic nerve antigen recognizes peptides  16 and 17  (Fig.  8 
E).  The  cross-reactive mAb 39/24C5  did not react  with 
any linear sequence of Ov39. 
T  Cell Response Assays.  The  T  cell  lines that  were  es- 
tablished are all specific for recombinant antigens that share 
A 41.7%  identity  B30.8% idemiW 
129  RTLIUDKRTGEI 140  133  UDKATGEILNPDE 145 
III  I  :  I:  ::1  ::111:  =: 
88  RTLNYDLKKQEL  99  99 LSKLREEILSKKQ 111 
C 60% Identity  D 62.5% identity 
113  PDERW 147  248  DTPIUYNK 255 
Ill::  I  I1:  II 
55  PDEUR 59  18  DLPIRENK 25 
Figure 7.  Identifies between the deduced protein sequence of hr44 
and Ov39 (SwissProt, accession  No. P31730). The top sequence in each 
alignment represents hr44 compared with the sequence of Ov39 that is 
printed underneath. Numbers indicate the amino acid residue position 
within the respective sequence. 
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2  RKSSNNCRUP 
3  SNNCRVPPFV 
4  CRUPPFVGDL 
5  PPFUODLPIR 
S  UOOLPIREHK 
7  LPIRIEHKEUL 
8  RENKEULSIW 
9  KEULSlWKDY 
I0 LSlMKDYKSG 
II  WKDYKSGEOC 
12 YKSOEDCSNQ 
13 OEDCSNQRRE 
14 CSHQRRETQQ 
15 QRRETQQUID 
16 ETQQUIODLP 
17 QUIDOLPOEV 
10 DOLPDEURRM 
19  POEURflMUFG 
20 URRNUFGflLP 
21  flUFORLPSFL 
22 GRLPSFLNGfl 
23 PSFLNGRSTD 
24 LNOflSTDUKK 
25 RSTOVKKMFR 
26 DUKKMFRfllM 
27 KMFRAInYNR 
ZO RRIflYNRTLN 
29 MYHRTLNYOL 
30 RTLHYDLKKQ 
31NYOLKKQELS 
32 LKKQELSKL8 
33  QELSKLREEI 
34 SKLREEILSK 
35 8EEILSKKQL 
35  ILSKKQLAEF 
00.5  1  1.5  2  2.5 
Optical Density at 410 nm 
0.5  1  1.5  2  2.50  0.5  1  1.5  2  2.500.511.522.533.500.511.522.533.5 
C  D 
I 
I 
/ 
I 
I 
I 
B 
I  Figure  8.  Mapping  of  linear 
epitopes of Ov39 by ELISA. Pep- 
tide 1 represents the amino-termi- 
nal 10 amino acids of Ov39. Each 
peptide consists of 10 residues that 
overlap the preceeding peptide by 
7 residues. (A)  Serum to the  ex- 
pressed carrier ofpEX34b. (/3) Se- 
rum  to  Ov39  expressed from 
pEX34b. (C") Serum to Ov39 ex- 
pressed from pGEXI.  (D) Rabbit 
serum taken before immunization 
with  the  native 44,000-M  r ocular 
antigen.  (E)  Serum  to  the  native 
44,000-M, antigen. 
the  same  carrier  peptide.  These  are  Ov39,  hr44,  and 
Ov3.11  (Fig. 9). The cell line specific for Ov3.11  was used 
as  control  and  was  shown  to  respond  only  to  antigen 
Ov3.11  (Fig.  9  A).  The  synthetic  carrier peptide  derived 
from pTrcHisB was used as a control and does not stimu- 
late  the  Ov3.11-specific  T  cell line  nor the  cell lines  spe- 
cific for Ov39 or hr44  (Fig. 9, B and C). hr44-specific cells 
respond to the  homologous  challenge  with hr44  and with 
both the truncated  molecules,  hr44-Sal  and hr44-3.  Back- 
ground incorporation obtained without stimulation is high- 
est for hr44-specific  cells  and  similar  counts  to  the  back- 
ground  are  obtained  after  stimulation  with  Ov39  and 
Ov3.11.  In contrast,  T  cells specific for Ov39 show prolif- 
erative responses to both the derivative molecules of hr44. 
These cells,  however,  do  not respond  to the  entire  mole- 
cule ofhr44. 
Immunocytochemical Localization.  The  immunocytochem- 
ical localization  of the ocular antigen was conducted  using 
rabbit antiserum to the  native 44,000-Mr  antigen  and  two 
mAbs,  44/72C2,  which  is  specific  for  the  recombinant 
hr44 antigen, and 39/24C5,  which has been shown to react 
with  hr44  and  the  parasite  antigen  Ov39  (Fig.  10).  The 
44,000-M  r antigen is detectable in all neural-derived tissues 
of the eye, including the optic nerve (Fig.  10, A  and B), the 
retina,  the  retinal  pigment  epithelium  (Fig.  10,  C-F),  the 
epithelial  (neural-derived)  layers  of the  iris,  ciliary  body, 
and pars plana (Fig.  10,  G-J). The inner and outer segments 
of the photoreceptor  cells were not stained  except for the 
myoid  region.  This  region  of  the  photoreceptors  was 
stained  by  44/72C2  but  not  by  the  other  reagents.  This 
mAb also showed stronger reactivity with both the  retinal 
pigment epithelium and ciliary and iris epithelium than the 
other two reagents. 
Discussion 
The role of molecular mimicry in autoimmunity (29-31) 
finds  increasing  support  as  mechanisms  are  identified  that 
show  how  a  sustained  autoimmune  response  can  develop 
from serologically  cross-reactive  antigens  that  involve  not 
only B  cells but  also allow priming of autoreactive  T  cells 
(32).  Ov39 and hr44 are antigens that may drive such a re- 
sponse.  These  antigens  are not  homologous  and  the  sero- 
logical  crossreactivity seems to be based  on  coincidentally 
shared conformational structures  similar enough  to engage 
Ab  cross-reactivity.  This  is supported  by the  reactivity of 
the mAb 39/24C5  that has affinity for both molecules but 
does not recognize any decamer peptides of Ov39.  In con- 
trast, polyclonal sera to Ov39 and the native ocular antigen 
react with a peptide of Ov39 (QVIDDLPDEV),  for which 
some sequence identity with hr44 was found  (PDEA,  resi- 
due  143-147).  Various  degrees  of identity was  also  found 
for other peptides  of Ov39 and hr44.  The contribution  of 
the corresponding peptides to the antigenicity of Ov39 and 
hr44 will be entirely dependent on the conformation of the 
native proteins.  These peptides,  therefore,  may or may not 
contribute  to  the  formation  of a  nonlinear  cross-reactive 
epitope. 
Ov39  and  hr44  may share  at  least  one  T  cell  epitope, 
since  rat  T  cells specific  for Ov39  can be stimulated  with 
both truncated versions ofhr44,  hr44-Sal, and hr44-3.  This 
1126  Cross-reactivity of Onchocerca volvulus with hr44,  a Human Ocular Antigen Figure  9.  T cell response assays. (A) T cell line specific for Ov3.11.  (B) 
T  cell line specific for Ov39.  (C) T  cell line specific for hr44.  The first 
column in each graph demonstrates the background  counts without addi- 
tion of antigen.  The antigens used for stimulation  were Ov39, Ov3.11, 
hr44, hr44-Sal,  hr44-3,  and the synthetic peptide  representing  the carrier 
ofpTrcHisB, m, Ov39; El, hr44; [], hr44-Sal; k~, hr44-3; B, Ov3.11; m, 
carrier. 
suggests  that the cross-reactive epitope(s) is located within 
the  amino-terminal  219  amino  acid  residues.  The  full- 
length  molecule  of hr44,  however,  does  not  stimulate 
Ov39-specific T  cells. The hydrophobic carboxy terminus 
of hr44 does not appear to influence the uptake by APCs, 
since  hr44-specific T  cells  responded to  stimulation  with 
the full-length molecule. The various derivative molecules 
of hr44 may be processed in different ways, generating the 
cross-reactive  epitope  from  the  truncated  molecules  of 
hr44  but probably not  at  all,  or  not  sufficiently enough, 
from the full-length antigen. Contamination of the antigen 
preparations  with  bacterial  components  can  be  excluded 
since Ov3.11-specific cells are not stimulated by any other 
antigen prepared from the same bacterial strain.  The carrier 
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peptide common to all antigens may also be excluded as a 
potential source of cross-reactivity since none of the T  cell 
lines  responded  to  stimulation  with  the  synthetic  carrier 
molecule. 
Several  mechanisms  of antigen  processing  have  been 
suggested to be responsible for the generation of either im- 
munodominant  or  cryptic  epitopes  (33).  In  healthy  hu- 
mans, there exists an extensive T  cell repertoire that seems 
to have escaped tolerance and is directed against  determi- 
nants that are considered nondominant (34).  In the devel- 
opment of pathology recruitment of these cells may play a 
vital  role.  It  has  been  speculated  that  the  initial  priming 
event could be by exposure to a dominant determinant on 
a  protein  from an  infective agent  that  may induce  a  re- 
sponse that is cross-reactive with a cryptic self determinant 
(35).  In Ov39, the cross-reactive epitope seems dominant, 
since Ov39-specific T  cells  still respond to truncated ver- 
sions of hr44 after repeated stimulation with Ov39. The T 
cell repertoire specific for hr44 does not contain or main- 
tain a population ofT cells that respond to stimulation with 
Ov39. Consequently, it is possible that the cross-reactive T 
cell  epitope  of hr44  is  subdominant  or  cryptic and  may 
only be generated from the truncated derivatives ofhr44. 
The cross-reactive T  cell epitope(s) may be within the 
peptides for which primary sequence identities have been 
found. A peptide derived from Ov39 (residue 88-111) and 
a  peptide  derived  from  hr44  (residue  129-145)  can  be 
matched  in  two  different alignments  and  may  therefore 
make a good candidate for a cross-reactive T  cell epitope. 
The peptide ofhr44 consisting of residue 123-139, also has 
identity with the conserved consensus of a  defined motif, 
the "HLA-DR.cd' motif that has been described for seven 
human proteins, four of which are implicated in develop- 
ment of autoimmune  disease.  These include  HLA-DRa, 
glutamic acid decarboxylase, heat shock protein 65, and in- 
sulin receptor (36).  For HLA-DR.o~,  this sequence has been 
identified as a selfT cell epitope (37). 
Although the amino terminus with a potential signal se- 
quence has not been cloned, analysis of the primary struc- 
ture suggests  that hr44 is a type I membrane protein with 
an amino-terminal extracytosohc domain, a transmemhrane 
domain,  and a very short carboxy-terminal cytosolic frag- 
ment consisting of basic  residues. Such residues are vital in 
determining the topology of transmembrane proteins  (26, 
38), and they tend to be localized in those parts of the pro- 
tein that have not been translocated across the bilayer (39). 
The residues that constitute the cytoplasmic domain can be 
comprised of as few as three amino  acid residues  (40).  In 
addition,  the  protein  also  has  homologies  with  the  pro- 
posed cleavage and GPI attachment sequences of some ad- 
hesion molecules (28). Hr44 may be the primary translation 
product and, similar to some other GPI anchored proteins, 
the hydrophobic carboxy terminal sequence may serve as 
an intermediate transmembrane  anchor for the protein in 
the endoplasmic reticulum before the formation of the gly- 
cophospholipid anchor.  Isoforms of surface molecules as- 
cribed to  the  generation of alternative splice products,  as 
shown for N-CAM, have also been identified. By Western Figure 10. 
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tigen often appears as a doublet (15). 
Hr44 has no cysteine residues that would allow for disul- 
fide bridges and formation of Ig-like C2 domains, as shown 
for many eucaryotic surface molecules involved in cell ad- 
hesion.  Since  antiserum  to  the  native  antigen  recognizes 
the recombinant hr44 molecule, extensive posttranslational 
modification may not occur, hr44, however, has 20 poten- 
tial  N-glycosylation  sites  and  2  serine-threonine  clusters 
that  could  serve  as  acceptors  for  O-linked  carbohydrates 
(41).  It does not show glycosaminoglycan attachment sites 
that  contain  features  of the  described consensus  acceptors 
(42,  43).  The calculated molecular mass of the fusion pro- 
tein expressed from pTrcHisB is 41.957,33 D, of which the 
amino terminal carrier peptide contributes 4.676 D. This is 
not  consistent with  the  electrophoretic mobility of hr44. 
The aberrant slow migration ofhr44 may be due to its high 
content  of prolines  and  basic  residues  (44).  The  proline- 
rich repeat region may serve as  a  hinge,  conferring some 
flexibility to the extracytosolic part of the molecule. 
The mAbs to Ov39 and hr44 and the rabbit serum raised 
to the native ocular antigen localize hr44  in the plexiform 
layers of the retina that are particularly rich in membrane 
structures.  The  myoid region  of the  photoreceptor  cells, 
which  was  stained by the mAb 44/72C2,  is known  to be 
the location of Golgi bodies and endoplasmic reticulum in 
these cells, and staining may result from reactivity with newly 
synthesized protein. 
The membrane-associated antigen localized in the neu- 
rotissue and the blood-ocular bamer may become the target 
of antiparasite-directed, Ab-dependent  cellular cytotoxic- 
ity, as well as complement-mediated cell lysis by formation 
ofa cytocidal membrane attack complex (MAC). Most hu- 
man  cells  and  tissues  are  protected  against  complement- 
mediated  lysis  by  expression  of an  inhibitory  molecule 
CD59  (45). However, the absence of CD59 from some cell 
types, such as oligodendrocytes (46)  in the central nervous 
system,  which  includes  the  optic  nerve,  may make  these 
cells susceptible to  MAC  attack  in  conditions where  the 
blood-tissue barrier is damaged. 
Direct  sequence  comparisons  between  host  molecules 
and molecules from potentially infective agents by search- 
ing protein data bases have frequently been used to suggest 
potential  immunological  cross-reactions.  Using  this  ap- 
proach it was found that an Ov39-derived peptide is iden- 
tical to an octapeptide of human  rhodopsin,  CAAPPFAG, 
except for two  conserved exchanges.  The biological turn- 
over  of photoreceptor  outer  segment  involves  ingestion 
and degradation of rod outer segment material by the reti- 
nal pigment epithelium (47). Rhodopsin may be presented 
by those cells in the context of HLA molecules or released 
from  damaged  retinal  pigment  epithelial  cells.  This  se- 
quence  of rhodopsin is not found in any of the three hu- 
man cone pigments.  This may be of relevance when  con- 
sidering  the  typical  sparing  of  the  macula  seen  in  eyes 
affected with otherwise widespread chorioretinal lesions. 
The immune  responses to a  diversity of retinal antigens 
in human  infection sera has been reported before (48-50) 
and may be explained by determinant spreading (51) caused 
by an underlying disease process. We suggest that cross-re- 
active cellular and humoral responses to hr44 might play a 
significant role in the initiation and perpetuation of ocular 
pathology seen in onchocerciasis. 
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Figure 10.  Immunocytochemical localization of the 44,000-M  r antigen in rat ocular tissues. (A) Hematoxylin and eosin staining of a section of optic 
nerve and retina (nr, neural retina; on, optic nerve). (B) Similar section immunostained with serum to the native 44,000-M~ antigen. The antigen is 
present in the inner layers of the neural retina and the entire optic nerve. (C) Neural retina stained with hematoxylin and eosin: ipl, inner plexiform layer; 
off, outer plexiform layer; is, photoreceptor inner segments; os, photoreceptor outer segments; rpe, retinal pigment epithelium. (D) Serum to the native 
44,000-Mr antigen. Reactivity is detectable throughout the neural retina, particularly in the plexiform layers with weaker staining of both the inner nu- 
clear layer and the outer nuclear layer (inl and onl, respectively). The photoreceptor inner and outer segments do not stain. Faint patchy staining of the 
retinal pigment epithelium can be seen. (E) mAb 44/72C2. A similar staining pattern apart from additional staining of the myoid region of the photore- 
ceptor inner segment (arrow) can be seen. (F) mAb 39/24C5 produces similar though less intense staining of  the neural retina. (G) Hematoxylin and eosin 
staining ot~ i, iris; cp, ciliary process; nr, peripheral neural retina. (H) Serum to the native 44,000-M  r antigen. Staining of the epithelial layers of the iris and 
ciliary processes  with stronger staining of the peripheral neural retina can be seen. (/) mAb 44/72C2. Staining of the epithelial layers of the iris and ciliary 
body and also the retinal pigment epithelium of the peripheral retina is detectable. ~  mAb 39/24C.  The staining is similar to but weaker than that ob- 
tained with the mAb to hr44. Bar, 200 p,m in A, B, G, and H-J, and 80 ~m in C-F. 
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